Mpm Asset Management buys $16,405,807 stake in Chiasma Inc (CHMA)

Chiasma Inc (CHMA) : Mpm Asset Management scooped up 54,752 additional shares in Chiasma Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 5,736,296 shares of Chiasma Inc which is valued at $16,405,807.Chiasma Inc makes up approximately 4.05% of Mpm Asset Management’s portfolio.

Other Hedge Funds, Including , Blair William Coil sold out all of its stake in CHMA during the most recent quarter. The investment firm sold 21,940 shares of CHMA which is valued $62,748. California State Teachers Retirement System sold out all of its stake in CHMA during the most recent quarter. The investment firm sold 15,646 shares of CHMA which is valued $42,557. Quantitative Systematic Strategies sold out all of its stake in CHMA during the most recent quarter. The investment firm sold 10,845 shares of CHMA which is valued $28,739.

Chiasma Inc opened for trading at $2.9 and hit $2.95 on the upside on Monday, eventually ending the session at $2.94, with a gain of 1.03% or 0.03 points. The heightened volatility saw the trading volume jump to 61,439 shares. Company has a market cap of $72 M.

Chiasma Inc. (Chiasma) is a biopharmaceutical company. The Company is focused on improving the lives of patients suffering from orphan diseases by developing and commercializing oral forms of therapies that are available by injection. Using the Company’s Transient Permeability Enhancer (TPE) technology platform it develops oral therapies associated with existing injectable therapies. It has completed a multinational Phase III clinical trial of its advanced Transient Permeability Enhancer platform-based product candidate oral octreotide for the treatment of acromegaly. The Company through its TPE platform has developed a pipeline of oral product candidates. It offers product oral octreotide for various indications such as Acromegaly-U.S. which has completed Phase III clinical trial; Acromegaly-E.U. which is in Phase III and Neuroendocrine Tumor (NET) and New indication (orphan). The Company’s wholly owned subsidiary is Chiasma (Israel) Ltd.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *